用户名:

密码:

验证码:

2019年

BET Inhibitors as Anticancer Agents: A Patent Review

2019-11-02 主编:诚信在线娱乐 点击次数 :

BET Inhibitors as Anticancer Agents: A Patent Review


BET Inhibitors as Anticancer Agents: A Patent Review

Author(s): , Bio-Organic Science Division, Korea Research Institute of Chemical Technology, Daejeon 34114, Korea , Bio-Organic Science Division, Korea Research Institute of Chemical Technology, Daejeon 34114, Korea . Bio-Organic Science Division, Korea Research Institute of Chemical Technology, Daejeon 34114, Korea

Affiliation:

Journal Name: Recent Patents on Anti-Cancer Drug Discovery

Volume 12 , Issue 4 , 2017

DOI : 10.2174/1574892812666170808121228

  Journal Home

Become EABM

Become Reviewer


Abstract:

Background: Bromodomain and Extra Terminal (BET) family of bromodomain proteins (BRDs), comprised of four members in humans (BRD2, BRD3, BRD4, and BRDT), has emerged as a promising new cancer target class for small-molecule drug discovery.

Objective: This review discusses the patent literature of BET inhibitors (2010-2017) for the treatment of cancer and other related diseases.

Method: BET proteins act as ‘epigenetic readers' and bind to acetylated lysine residues on the tails of histones H3 and H4. Inhibition of BET proteins for a wide array of therapeutic applications has led to the discovery and development of various BET inhibitors.

Results: The increasing significance of BET inhibitors as a potential anticancer therapeutic has led to an extensive patent activity both from academia and pharmaceutical industry. Several of the BET inhibitors are under clinical development for the treatment of various kinds of cancers.

Conclusion: The unmet needs and challenges associated with BET inhibition for cancer treatment have been portrayed in this review. An insight into the current developments and future prospects has been described as well.

Keywords: BET, BET inhibitors, BRDs, cancer, epigenetics, patent, therapeutic potential.

Recent Patents on Anti-Cancer Drug Discovery

Title:BET Inhibitors as Anticancer Agents: A Patent Review

VOLUME: 12 ISSUE: 4

Author(s):Imran Ali, Gildon Choi* and Kwangho Lee*

Affiliation:Bio-Organic Science Division, Korea Research Institute of Chemical Technology, Daejeon 34114, Bio-Organic Science Division, Korea Research Institute of Chemical Technology, Daejeon 34114, Bio-Organic Science Division, Korea Research Institute of Chemical Technology, Daejeon 34114

Keywords:BET, BET inhibitors, BRDs, cancer, epigenetics, patent, therapeutic potential.

Abstract:Background: Bromodomain and Extra Terminal (BET) family of bromodomain proteins (BRDs), comprised of four members in humans (BRD2, BRD3, BRD4, and BRDT), has emerged as a promising new cancer target class for small-molecule drug discovery.

Objective: This review discusses the patent literature of BET inhibitors (2010-2017) for the treatment of cancer and other related diseases.

Method: BET proteins act as ‘epigenetic readers' and bind to acetylated lysine residues on the tails of histones H3 and H4. Inhibition of BET proteins for a wide array of therapeutic applications has led to the discovery and development of various BET inhibitors.

Results: The increasing significance of BET inhibitors as a potential anticancer therapeutic has led to an extensive patent activity both from academia and pharmaceutical industry. Several of the BET inhibitors are under clinical development for the treatment of various kinds of cancers.

Conclusion: The unmet needs and challenges associated with BET inhibition for cancer treatment have been portrayed in this review. An insight into the current developments and future prospects has been described as well.

Close Print this page

Close

About this article

Cite this article as:

Imran Ali, Gildon Choi* and Kwangho Lee*, “BET Inhibitors as Anticancer Agents: A Patent Review”, Recent Patents on Anti-Cancer Drug Discovery (2017) 12: 340. https://doi.org/10.2174/1574892812666170808121228

DOI
https://doi.org/10.2174/1574892812666170808121228 Print ISSN
1574-8928

Publisher Name
Bentham Science Publisher Online ISSN
2212-3970



About this journal

Close

Article Details

VOLUME: 12
ISSUE: 4
Year: 2017
Page: [340 - 364]
Pages: 25
DOI: 10.2174/1574892812666170808121228
Price: $58

Article Metrics

PDF: 95
HTML: 14
EPUB: 1
PRC: 1

(责任编辑:诚信在线娱乐 登录,欢迎转载!)
文章人气:
(请您在发表言论时自觉遵守互联网相关政策法律法规,文明上网,健康言论。)
用户名:
验证码:
首页 | 新闻 | 财经 | 军事 | 百科 | 科技 | 数码 | 汽车 | 游戏 | 娱乐 | 体育 | 文化 | 教育 | 房产 | 旅游 | 健康 | 女性 | 明星 | 美女